PUR0200
Chronic Obstructive Pulmonary Disease (COPD)
Formulation DevelopmentLegacy Program
Key Facts
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Formulation Development
Status
Legacy Program
Company
About Pulmatrix
Pulmatrix is dedicated to improving the lives of patients with severe respiratory and other diseases through its innovative dry powder inhalation platform, iSPERSE™. This technology allows for high drug loads, efficient lung delivery, and stable formulations of challenging compounds. The company's lead program, PUR3100, is an inhaled dihydroergotamine (DHE) in development for acute migraine, representing a novel, non-systemic treatment approach. Pulmatrix's strategy includes advancing its proprietary pipeline and pursuing strategic collaborations to leverage its platform.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANORO ELLIPTA | Innoviva | Approved/Commercial |
| Verekitug | Upstream Bio | Phase 2 |
| FHD-909 | Fulcrum Therapeutics | Preclinical |